检验医学
檢驗醫學
검험의학
LABORATORY MEDICINE
2009年
12期
891-894
,共4页
孙立山%范列英%张慧%郑慧雅%宗明%朱海波
孫立山%範列英%張慧%鄭慧雅%宗明%硃海波
손립산%범렬영%장혜%정혜아%종명%주해파
糖皮质激素诱导的肿瘤坏死因子受体%糖皮质激素诱导的肿瘤坏死因子受体配体%酶联免疫吸附试验%类风湿性关节炎
糖皮質激素誘導的腫瘤壞死因子受體%糖皮質激素誘導的腫瘤壞死因子受體配體%酶聯免疫吸附試驗%類風濕性關節炎
당피질격소유도적종류배사인자수체%당피질격소유도적종류배사인자수체배체%매련면역흡부시험%류풍습성관절염
Glucocorticoid-induced tumor necrosis factor receptor%Glucocorticoid-induced tumor necrosis factor receptor ligand%Enzyme-linked immunosorbent assay%Rheumatoid arthritis
目的 建立测定糖皮质激素诱导的肿瘤坏死因子受体(GITR)及其配体(GITRL)的定量酶联免疫吸附试验(ELISA),并探讨GITR及GITRL定量测定在类风湿性关节炎(RA)及肿瘤疾病的诊断或病情监测中的临床应用.方法 以鼠抗人GITR、GITRL单克隆抗体为包被抗体,以生物素-辣根过氧化物酶标记链霉亲和素(SA-HRP)检测系统,建立GITR和GITRL 定量检测的双抗体夹心ELISA.测定105例RA患者、54例肿瘤患者及100名健康体检者的血清GITR、GITRL含量,并探讨其与疾病的关系.结果 建立的测定GITR、GITRL定量ELISA线性相关系数的平方(r~2)分别为0.94和0.90.RA组血清中GITR、GITRL含量均明显高于正常对照组(P均<0.001);肿瘤组GITR高于正常对照组(P<0.001),GITRL与正常对照组差异无统计学意义((P>)0.05).结论 本研究成功建立了GITR、GITRL定量ELISA,血清GITR、GITRL含量测定可能会成为RA新的辅助性诊断指标和病情监测指标.
目的 建立測定糖皮質激素誘導的腫瘤壞死因子受體(GITR)及其配體(GITRL)的定量酶聯免疫吸附試驗(ELISA),併探討GITR及GITRL定量測定在類風濕性關節炎(RA)及腫瘤疾病的診斷或病情鑑測中的臨床應用.方法 以鼠抗人GITR、GITRL單剋隆抗體為包被抗體,以生物素-辣根過氧化物酶標記鏈黴親和素(SA-HRP)檢測繫統,建立GITR和GITRL 定量檢測的雙抗體夾心ELISA.測定105例RA患者、54例腫瘤患者及100名健康體檢者的血清GITR、GITRL含量,併探討其與疾病的關繫.結果 建立的測定GITR、GITRL定量ELISA線性相關繫數的平方(r~2)分彆為0.94和0.90.RA組血清中GITR、GITRL含量均明顯高于正常對照組(P均<0.001);腫瘤組GITR高于正常對照組(P<0.001),GITRL與正常對照組差異無統計學意義((P>)0.05).結論 本研究成功建立瞭GITR、GITRL定量ELISA,血清GITR、GITRL含量測定可能會成為RA新的輔助性診斷指標和病情鑑測指標.
목적 건립측정당피질격소유도적종류배사인자수체(GITR)급기배체(GITRL)적정량매련면역흡부시험(ELISA),병탐토GITR급GITRL정량측정재류풍습성관절염(RA)급종류질병적진단혹병정감측중적림상응용.방법 이서항인GITR、GITRL단극륭항체위포피항체,이생물소-랄근과양화물매표기련매친화소(SA-HRP)검측계통,건립GITR화GITRL 정량검측적쌍항체협심ELISA.측정105례RA환자、54례종류환자급100명건강체검자적혈청GITR、GITRL함량,병탐토기여질병적관계.결과 건립적측정GITR、GITRL정량ELISA선성상관계수적평방(r~2)분별위0.94화0.90.RA조혈청중GITR、GITRL함량균명현고우정상대조조(P균<0.001);종류조GITR고우정상대조조(P<0.001),GITRL여정상대조조차이무통계학의의((P>)0.05).결론 본연구성공건립료GITR、GITRL정량ELISA,혈청GITR、GITRL함량측정가능회성위RA신적보조성진단지표화병정감측지표.
Objective To establish an enzyme-linked immunosorbent assay(ELISA) for measuring glucocorticoid-induced tumor necrosis factor receptor(GITR)and glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL), and explore the clinical application of the measurement of GITR and GITRL in the diagnosis and monitoring rheumatoid arthritis (RA) and tumor diseases. Methods With mouse monocolonal anti-human GITR and GITRL antibody as coating antibody and biotin-streptavidin-horseradish peroxidase (SA-HRP) as detecting system, a double antibodies sandwich ELISA was established for measuring GITR and GITRL. The serum levels of GITR and GITRL from 105 patients with RA, 54 patients with tumor and 100 healthy subjects were measured and the relationship of GITR and GITRL with RA and tumor diseases was analyzed. Results The correlation coefficient (r~2) was 0.94 for GITR assay and 0.90 for GITRL assay. The levels of GITR and GITRL in patients with RA were higher than those in healthy subjects (P<0.001). The levels of GITR in patients with tumor were higher than those in healthy subjects (P<(0.001)), and there was no significant difference for GITRL levels (P>0.05). Conclusions An ELISA for measuring the GITR and GITRL in serum is successfully established. GITR and GITRL in serum may be new assistant diagnostic or monitoring parameters for RA.
